AI assistant
Apellis Pharmaceuticals, Inc. — Director's Dealing 2017
Nov 8, 2017
31417_dirs_2017-11-08_40d62a2e-6f2d-4e9a-be74-253c8cc0566c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08
Reporting Person: Morningside Venture Investments Ltd (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Preferred Stock | $ | Common Stock (494394) | Direct | ||
| Series C Preferred Stock | $ | Common Stock (8063759) | Direct | ||
| Series D Preferred Stock | $ | Common Stock (2098581) | Direct | ||
| Series E Preferred Stock | $ | Common Stock (121566) | Direct |
Footnotes
F1: The Series B, Series C, Series D and Series E Preferred Stock are convertible into Common Stock on a 2.133-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
F2: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.